{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T18:10:10Z","timestamp":1759860610734,"version":"build-2065373602"},"reference-count":49,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["260931"],"award-info":[{"award-number":["260931"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cancer Foundation Finland sr, and Expert Responsibility Area of the Pirkanmaa Hospital District","award":["9V065"],"award-info":[{"award-number":["9V065"]}]},{"DOI":"10.13039\/501100010711","name":"Cancer Foundation Finland","doi-asserted-by":"crossref","award":["220055"],"award-info":[{"award-number":["220055"]}],"id":[{"id":"10.13039\/501100010711","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>The coagulation cascade is thought to contribute to cancer progression. Although <jats:italic>in vitro<\/jats:italic> studies suggest that anticoagulants, such as warfarin, might reduce cancer progression, epidemiological data indicate that warfarin users may have a higher risk of cancer mortality. However, single nucleotide polymorphisms (SNPs) that influence warfarin dosing might affect this association. We investigated the risk associations between warfarin use and prostate cancer (PCa) survival, considering the SNP genotypes of <jats:italic>CYP2C9<\/jats:italic> and <jats:italic>VKORC1<\/jats:italic>, which are known to impact both warfarin pharmacokinetics and pharmacodynamics, resulting in lower warfarin dose requirement. We genotyped 2,246 Finnish men with PCa from two different cohorts for SNPs rs1057910, rs1799853, and rs9923231. Genotyping was done using a custom Illumina iSelect genotyping array (iCOGs). Using Cox regression models, we calculated hazard ratios (HRs) and 95% confidence intervals (CI) for the risk of overall death, cancer deaths overall, and PCa-specific death after PCa diagnosis based on SNP genotypes. Data on warfarin purchases was obtained from a national registry. Our findings revealed that the SNPs did not alter the risk of cancer or PCa death in either cohort, nor did they modify the risk among warfarin users. However, overall mortality was higher among warfarin users compared to non-users, particularly in carriers of all three SNPs. Even though the increased mortality is likely due to confounding by indication, warfarin use may increase overall mortality especially in men with lower warfarin dose requirements due to SNP carrier status. However, we need further studies with larger populations to confirm these findings.<\/jats:p>","DOI":"10.1371\/journal.pone.0329438","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T17:28:57Z","timestamp":1759858137000},"page":"e0329438","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["SNP genotypes in CYP2C9 and VKORC1 genes do not affect prostate cancer or cancer mortality among warfarin users in Finnish prostate cancer patients"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2932-9590","authenticated-orcid":true,"given":"Teemu J.","family":"Murtola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaisa M.","family":"Skantsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aino","family":"Siltari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsi","family":"Talala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimmo","family":"Taari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teuvo L.J.","family":"Tammela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Schleutker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anssi","family":"Auvinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Csilla","family":"Sipeky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"issue":"1","key":"pone.0329438.ref001","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"RL Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"pone.0329438.ref002","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.euf.2018.04.001","article-title":"Impact of metabolic diseases, drugs, and dietary factors on prostate cancer risk, recurrence, and survival: a systematic review by the European Association of Urology Section of oncological urology","volume":"5","author":"R Campi","year":"2019","journal-title":"Eur Urol Focus"},{"issue":"5","key":"pone.0329438.ref003","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.euf.2018.02.007","article-title":"Latest evidence on the impact of smoking, sports, and sexual activity as modifiable lifestyle risk factors for prostate cancer incidence, recurrence, and progression: a systematic review of the literature by the European Association of Urology Section of Oncological Urology (ESOU)","volume":"5","author":"SD Brookman-May","year":"2019","journal-title":"Eur Urol Focus"},{"issue":"4","key":"pone.0329438.ref004","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00432-018-2596-6","article-title":"Impact of comorbidities at diagnosis on prostate cancer treatment and survival","volume":"144","author":"KL Matthes","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"pone.0329438.ref005","article-title":"Role of the coagulation system in genitourinary cancers: review","author":"A John","year":"2017","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"pone.0329438.ref006","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood-2014-08-531582","article-title":"Platelets at the interface of thrombosis, inflammation, and cancer","volume":"126","author":"AT Franco","year":"2015","journal-title":"Blood"},{"issue":"1","key":"pone.0329438.ref007","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10555-014-9498-0","article-title":"Platelets and cancer: a casual or causal relationship: revisited","volume":"33","author":"DG Menter","year":"2014","journal-title":"Cancer Metastasis Rev"},{"key":"pone.0329438.ref008","article-title":"Effects of platelets on cancer progression","author":"L Plantureux","year":"2018","journal-title":"Thromb Res"},{"issue":"6","key":"pone.0329438.ref009","first-page":"1217","article-title":"A study of the mechanism by which anticoagulation with warfarin inhibits blood-borne metastases","volume":"33","author":"JM Brown","year":"1973","journal-title":"Cancer Res"},{"issue":"10","key":"pone.0329438.ref010","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/bjs.1800741005","article-title":"Warfarin inhibition of metastasis: the role of anticoagulation","volume":"74","author":"P McCulloch","year":"1987","journal-title":"Br J Surg"},{"issue":"1","key":"pone.0329438.ref011","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood-2013-02-485011","article-title":"Anticoagulation inhibits tumor cell-mediated release of platelet angiogenic proteins and diminishes platelet angiogenic response","volume":"123","author":"EM Battinelli","year":"2014","journal-title":"Blood"},{"key":"pone.0329438.ref012","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1470-2045(07)70046-3","article-title":"Use of warfarin and risk of urogenital cancer: a population-based, nested case-control study","volume":"8","author":"V Tagalakis","year":"2007","journal-title":"Lancet Oncol"},{"issue":"6","key":"pone.0329438.ref013","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/21681805.2016.1228085","article-title":"Warfarin use and prostate cancer risk in the Finnish Randomized Study of Screening for prostate cancer","volume":"50","author":"PTT Kinnunen","year":"2016","journal-title":"Scand J Urol"},{"issue":"1","key":"pone.0329438.ref014","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1186\/s12885-017-3579-8","article-title":"Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer","volume":"17","author":"PTT Kinnunen","year":"2017","journal-title":"BMC Cancer"},{"issue":"5","key":"pone.0329438.ref015","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1182\/blood-2010-08-304758","article-title":"Long-term use of vitamin K antagonists and incidence of cancer: a population-based study","volume":"117","author":"V Pengo","year":"2011","journal-title":"Blood"},{"key":"pone.0329438.ref016","doi-asserted-by":"crossref","DOI":"10.1038\/sj.bjc.6605602","article-title":"Antithrombotic therapy and survival in patients with malignant disease","volume":"102","author":"AK Kakkar","year":"2010","journal-title":"Br J Cancer"},{"key":"pone.0329438.ref017","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/cncr.25714","article-title":"Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis","volume":"117","author":"GH Lyman","year":"2011","journal-title":"Cancer"},{"issue":"2","key":"pone.0329438.ref018","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1055\/s-2007-996089","article-title":"The natural history of deep-vein thrombosis","volume":"23","author":"P Prandoni","year":"1997","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"pone.0329438.ref019","doi-asserted-by":"crossref","first-page":"54","DOI":"10.5482\/HAMO-13-10-0054","article-title":"Platelets in cancer and thrombosis","volume":"34","author":"J Riedl","year":"2014","journal-title":"Hamostaseologie"},{"issue":"10","key":"pone.0329438.ref020","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11886-018-1034-3","article-title":"Venous thromboembolism and cancer","volume":"20","author":"AA Schmaier","year":"2018","journal-title":"Curr Cardiol Rep"},{"issue":"25","key":"pone.0329438.ref021","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJM200012213432504","article-title":"Prognosis of cancers associated with venous thromboembolism","volume":"343","author":"HT S\u00f8rensen","year":"2000","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0329438.ref022","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S1470-2045(10)70038-3","article-title":"Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden","volume":"11","author":"M Van Hemelrijck","year":"2010","journal-title":"Lancet Oncol"},{"issue":"4","key":"pone.0329438.ref023","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/clpt.2011.185","article-title":"Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing","volume":"90","author":"JA Johnson","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"pone.0329438.ref024","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1055\/s-0032-1328891","article-title":"Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin","volume":"38","author":"E Fung","year":"2012","journal-title":"Semin Thromb Hemost"},{"key":"pone.0329438.ref025","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/FTD.0000000000000192","article-title":"Clinical practice recommendations on genetic testing of CYP2C9 and VKORC1 variants in warfarin therapy","volume":"37","author":"K Shaw","year":"2015","journal-title":"Ther Drug Monit"},{"key":"pone.0329438.ref026","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00439-006-0260-8","article-title":"Association of warfarin dose with genes involved in its action and metabolism","volume":"121","author":"M Wadelius","year":"2007","journal-title":"Hum Genet"},{"issue":"10","key":"pone.0329438.ref027","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/jnci\/djt038","article-title":"Prostate cancer mortality in the Finnish randomized screening trial","volume":"105","author":"TP Kilpel\u00e4inen","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"pone.0329438.ref028","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/028418602760169442","article-title":"The Finnish Cancer Registry as follow-up source of a large trial cohort--accuracy and delay","volume":"41","author":"P Korhonen","year":"2002","journal-title":"Acta Oncol"},{"key":"pone.0329438.ref029","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejca.2017.02.017","article-title":"Quality measures of the population-based Finnish Cancer Registry indicate sound data quality for solid malignant tumours","volume":"77","author":"MK Leinonen","year":"2017","journal-title":"Eur J Cancer"},{"key":"pone.0329438.ref030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canep.2016.08.022","article-title":"Estimating bias in causes of death ascertainment in the Finnish Randomized Study of screening for prostate cancer","volume":"45","author":"TP Kilpel\u00e4inen","year":"2016","journal-title":"Cancer Epidemiol"},{"key":"pone.0329438.ref031","unstructured":"WHOCC - ATC\/DDD Index. [Accessed 2024 March 19]. https:\/\/www.whocc.no\/atc_ddd_index\/"},{"issue":"1","key":"pone.0329438.ref032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jpm8010001","article-title":"Pharmacogenomics of CYP2C9: functional and clinical considerations","volume":"8","author":"AK Daly","year":"2017","journal-title":"J Pers Med"},{"key":"pone.0329438.ref033","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cca.2007.02.033","article-title":"The association of CYP2C9 gene polymorphisms with colorectal carcinoma in Han Chinese","volume":"380","author":"LH Liao","year":"2007","journal-title":"Clin Chim Acta"},{"issue":"3","key":"pone.0329438.ref034","article-title":"Vitamin K epoxide reductase expression and prostate cancer risk","volume":"35","author":"BY Tew","year":"2017","journal-title":"Urol Oncol"},{"issue":"12","key":"pone.0329438.ref035","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1038\/s41588-023-01534-4","article-title":"Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants","volume":"55","author":"A Wang","year":"2023","journal-title":"Nat Genet"},{"issue":"5","key":"pone.0329438.ref036","article-title":"Activation of blood coagulation in cancer: implications for tumour progression","volume":"33","author":"LG Lima","year":"2013","journal-title":"Biosci Rep"},{"key":"pone.0329438.ref037","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1515\/CCLM.2000.099","article-title":"Changes of the coagulation and fibrinolysis system in malignancy: their possible impact on future diagnostic and therapeutic procedures","volume":"38","author":"W Korte","year":"2000","journal-title":"Clin Chem Lab Med"},{"issue":"2","key":"pone.0329438.ref038","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1160\/TH16-08-0615","article-title":"Cancer-associated venous thromboembolism: burden, mechanisms, and management","volume":"117","author":"C Ay","year":"2017","journal-title":"Thromb Haemost"},{"key":"pone.0329438.ref039","first-page":"1079","article-title":"Risk of prostate cancer death in long-term users of warfarin: a population-based case-control study","volume":"24","author":"V Tagalakis","year":"2013","journal-title":"Cancer Causes Control"},{"key":"pone.0329438.ref040","first-page":"355","article-title":"The effect of warfarin therapy on breast, colorectal, lung, and prostate cancer survival: a population-based cohort study using the Clinical Practice Research Datalink","volume":"26","author":"MA O\u2019Rorke","year":"2015","journal-title":"Cancer Causes Control"},{"issue":"1","key":"pone.0329438.ref041","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.clgc.2014.04.008","article-title":"The effect of therapeutic anticoagulation on overall survival in men receiving first-line docetaxel chemotherapy for metastatic castration-resistant prostate cancer","volume":"13","author":"JC Park","year":"2015","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"pone.0329438.ref042","article-title":"Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer","volume":"6","author":"LA Kahale","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"pone.0329438.ref043","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12916-018-1093-8","article-title":"Genotype-guided versus traditional clinical dosing of warfarin in patients of Asian ancestry: a randomized controlled trial","volume":"16","author":"NL Syn","year":"2018","journal-title":"BMC Med"},{"issue":"1","key":"pone.0329438.ref044","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-016980","article-title":"Time in therapeutic range and stability over time for warfarin users in clinical practice: a retrospective cohort study using linked routinely collected health data in Alberta, Canada","volume":"8","author":"FA McAlister","year":"2018","journal-title":"BMJ Open"},{"issue":"2","key":"pone.0329438.ref045","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.jfma.2018.07.021","article-title":"Comparison of warfarin dosage fluctuation with time in therapeutic range for bleeding or thromboembolism rate in Chinese patients","volume":"118","author":"H-Y Yu","year":"2019","journal-title":"J Formos Med Assoc"},{"issue":"10","key":"pone.0329438.ref046","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"P Prandoni","year":"2002","journal-title":"Blood"},{"issue":"10","key":"pone.0329438.ref047","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1093\/hmg\/8.10.1913","article-title":"Molecular genetics of the Finnish disease heritage","volume":"8","author":"L Peltonen","year":"1999","journal-title":"Hum Mol Genet"},{"issue":"21","key":"pone.0329438.ref048","doi-asserted-by":"crossref","first-page":"12416","DOI":"10.1073\/pnas.95.21.12416","article-title":"Linkage disequilibrium mapping in isolated populations: the example of Finland revisited","volume":"95","author":"A de la Chapelle","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"pone.0329438.ref049","first-page":"697","article-title":"Messages from an isolate: lessons from the Finnish gene pool","volume":"376","author":"L Peltonen","year":"1995","journal-title":"Biol Chem Hoppe Seyler"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0329438","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T17:29:11Z","timestamp":1759858151000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0329438"}},"subtitle":[],"editor":[{"given":"Maciej","family":"Huk","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":49,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0329438","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]}}}